Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study-Reference-Cited by-同舟云学术

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Published:2023-08-26 Issue:6 Volume:12 Page:1937-1958
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Aldred Jason^ORCID,Freire-Alvarez Eric^ORCID,Amelin Alexander V.^ORCID,Antonini Angelo^ORCID,Bergmans Bruno^ORCID,Bergquist Filip^ORCID,Bouchard Manon,Budur Kumar,Carroll Camille^ORCID,Chaudhuri K. Ray^ORCID,Criswell Susan R.^ORCID,Danielsen Erik H.,Gandor Florin^ORCID,Jia Jia,Kimber Thomas E.^ORCID,Mochizuki Hideki^ORCID,Robieson Weining Z.^ORCID,Spiegel Amy M.,Standaert David G.^ORCID,Talapala Saritha,Facheris Maurizio F.,Fung Victor S. C.^ORCID

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-023-00533-1.pdf

Reference51 articles.

1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–9.

2. Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009;62(1):1–8.

3. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677–87.